# Tirzepatide in Adolescents With Obesity The SURMOUNT-ADOLESCENTS Randomized Clinical Trial

> **Open Intelligence Dossier** · First detected: 2026-11-19 13:20 UTC · Category: Health

## Executive Summary
Tirzepatide led to substantial BMI reductions in adolescents with obesity during the phase III SURMOUNT-ADOLESCENTS trial.

## Intelligence Brief
MedPage Today reported that once-weekly tirzepatide, known as Zepbound, paired with a healthy lifestyle intervention, yielded an 18.5% mean BMI reduction at week 72 compared with a 0.5% increase with a placebo. The trial met its primary endpoint for superiority, showing an estimated treatment difference of -19.0 percentage points. Aaron S. Kelly, PhD, of the University of Minnesota Medical School and his colleagues presented these findings at the ObesityWeek annual meeting while simultaneously publishing them in JAMA. According to MedPage Today, the trial enrolled 160 adolescents aged 12 to less than 18 years across 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the United States from October 2023 to June 2026. Participants had obesity or overweight with obesity-related complications. At baseline, the average participant age was 14.6 years, 61.9% were female, the mean weight was 242 lb, and the mean BMI was 38.6. Following a 12-week healthy lifestyle lead-in, participants were randomized 2:1 to receive subcutaneous tirzepatide or a placebo alongside ongoing diet and physical activity counseling. The tirzepatide group escalated to a maximum tolerated dose of 5, 10, or 15 mg. MedPage Today noted that 61.6% of trial completers reached the 15-mg dose at week 72. All 10 key secondary outcomes significantly favored tirzepatide, including reductions in waist circumference and body weight alongside improvements in physical functioning. Over half of the participants treated with tirzepatide, specifically 53.5%, no longer met the clinical threshold for obesity at week 72, compared with 7.1% of those taking the placebo. Furthermore, 48.1% of tirzepatide-treated participants achieved at least a 20% reduction in BMI. Gastrointestinal events were reported as the most common adverse events, affecting 81.5% of the tirzepatide group compared with 54.9% of the placebo group. Most of these events were mild to moderate and occurred during dose escalation. Among participants who received at least one tirzepatide dose, 9.3% discontinued due to adverse events, while no participants in the placebo group discontinued for that reason. In an accompanying editorial, William Heerman, MD, MPH, of Vanderbilt Health and his colleagues cautioned against a reflexive dose escalation to the maximum tolerated dose, suggesting instead that clinicians individualize titration based on treatment response, side effects, and nutritional adequacy. Editorialists also pointed out a lack of racial and ethnic diversity in the trial, noting that participants were 83.4% white and 96.9% non-Hispanic.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Clinical Trials Arena | AHA 2026: Tirzepatide Improves Key Biomarkers in Obesity-Related Heart Failure | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxQTFBCNnF4RTlXR1JoTXJBYWx0TVVMZmVjU2g2TnhMaVplV2draDNqdy01UmNycV9ZNzFzY003N0gwcmI5LWdhbW1IQ05jX1ZlVVRrdVVlTWZJYzNJRGRqeXZVVWw3WHItc3pUVjRpMjhmcGpOUDhqVFdiY1MwYWJpNUhERDhJSE1LR0FrVTc1REZ4RzdxNlZza0xBS29CVTB6Zi01dDVmRHM5Y2RMRlhwYWpLRTVYSm9nV29UMVo3eGY1UVpDOEdMWnNR?oc=5) |
| Bloomberg.com | Lilly’s Obesity Drug Zepbound Helped Adolescents Lose Weight | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxNbm0zT1dYSk1mZVFMZEgweVdMUWxGaUxYTEhjci10LWRmWmN5enRqTTVhNHRtWTBUSE50TXJ0SnZrR0MzaWdxak8yQmpUaF9JODhZc19QVHlKcWRGR1RJVk9Cckc2MV84c2dOZDMyVzNaVUFYVFYyVm1lakZjSFdPanFza2g4ZURROGQ5ZjNXU1VhU0xJZG96RE00ZFJCSkpJOVhqdTdWdXdrMktBQWNaSQ?oc=5) |
| MedPage Today | Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial | [Source Link](https://news.google.com/rss/articles/CBMicEFVX3lxTE5FS0dDVVF4bUpLbHpOeFhWMDdQdE45bTczSnJlSndkVnd0eTlqZFZrSHU5VTlhTUdYM0lxWE9TaDVGMzR1c1NjYjBtd29CZHV0bWR5aFFZSHk2ZWRLTVRkRURJUUVYdnEtaFVOcC1QbDk?oc=5) |
| Medical Xpress | Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOOUFNczluLVRuaHNabTB6Y2ZZLVdaTnR1MHl6cjFxSU5qNXdGY2JaV0tfRDlDb1ktOG1ZR1ZNa09Ec0tJSWJSODVjUHlvd3VtbkFDY3VRS0t0aDdLb0pwc1ZweHQxdDZPSVA3M2NrdkEtVkV6V3lJR3V2Rlp1Y1lGd0pNS1BXcUtMZVIxckQxTjdqZw?oc=5) |
| JAMA | Tirzepatide in Adolescents With Obesity The SURMOUNT-ADOLESCENTS Randomized Clinical Trial | [Source Link](https://news.google.com/rss/articles/CBMiaEFVX3lxTE9SdjJHWE1XQjAwQVhYVVQzZERjOThmMjJFRlBFazdoWTBJa3JIdmljNDlKOTlYS0ljYTEwZ0JJX1FFX1JsdGdNWnAtTk80Qkc5WFFOTkMySXMxMnpaQ2JsUG5NVktEVkhr?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-19/tirzepatide-in-adolescents-with-obesity-the-surmount-adolescents-randomized*
